Ustekinumab, vedolizumab ‘good treatment options’ for Crohn’s disease of the pouch
Ustekinumab and vedolizumab both demonstrated safety and efficacy in treating Crohn’s disease of the pouch, according to research published in Inflammatory Bowel Diseases.“Refractory CD of the pouch has historically been treated with anti-tumor necrosis factor therapies,” study lead author Sunhee Park, MD, associate clinical professor of medicine at the University of California,